Prenetics Global Ltd (PRE)
5.78
-0.16
(-2.69%)
USD |
NASDAQ |
Dec 16, 16:00
6.00
+0.22
(+3.81%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 70.62M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 40.98% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.784 |
| Price to Book Value | 0.3952 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by ‘enhancing life through science’. |
| URL | https://www.prenetics.com |
| Investor Relations URL | https://ir.prenetics.com/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Apr. 02, 2025 (est.) |
| Last Earnings Release | Nov. 27, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by ‘enhancing life through science’. |
| URL | https://www.prenetics.com |
| Investor Relations URL | https://ir.prenetics.com/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Apr. 02, 2025 (est.) |
| Last Earnings Release | Nov. 27, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |